Xanthine oxidase-IN-6

Cat. No.: HY-146560: FAQs
Data Sheet Handling Instructions

Molarity Calculator

Xanthine oxidase-IN-6 (Compound 6c) is a potent, orally active, mixed-type xanthine oxidase (XOD) inhibitor with an IC₅₀ value of 1.37 µM. Xanthine oxidase-IN-6 shows strong anti-hyperuricemia and renal protective activity.

For research use only. We do not sell to patients.

Xanthine oxidase-IN-6 Chemical Structure

Size		Stock
MOQ		Minimum order quantity
50 mg		Get quote
100 mg		Get quote
250 mg		Get quote
Other size		Get quote

Synthetic products have potential research and development risk.

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

View All NF-κB Isoform Specific Products:

View All Isoforms

NF-κB NF-κB1/p50 RelA/p65 RelB c-Rel

View All Toll-like Receptor (TLR) Isoform Specific Products:

View All Isoforms

TLR3 TLR8 TLR9 TLR2 TLR4 TLR7 TLR1 TLR6

View All TNF Receptor Isoform Specific Products:

View All Isoforms

TNFRSF1A/CD120a TNFRSF5/CD40 TNFRSF6/Fas/CD95 TNFRSF8/CD30 TNFRSF9/4-1BB/CD137 TNFRSF16/NGF Receptor/CD271 TNFRSF18/GITR/CD357

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target

XOD

1.37 μM (IC₅₀)

NF-κB

TLR4

In Vitro

Xanthine oxidase-IN-6 (Compound 6c) is a mixed-type XOD inhibitor, preferentially bound to the free enzyme and not the enzyme substrate complex^[1].
Xanthine oxidase-IN-6 is stable in simulated gastrointestinal digestion, with hydrolysis half-life more than 4 h^[1].
Xanthine oxidase-IN-6 (0-100 µM) exhibits an obvious anti-inflammatory effect by reducing the level of inflammatory factors (TGF-β, TNF-α and IL-1β) in a dose-dependent manner^[1].
Xanthine oxidase-IN-6 (0-100 µM, 48 h) inhibits HK-2 cell epithelial mesenchymal transition under high level of uric acid^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:	HK-2 cells
Concentration:	12.5, 25, 50, and 100 µM
Incubation Time:	48 h
Result:	Reduced the protein levels of α-SMA and Collagen I in a dose-dependent manner

In Vivo

Xanthine oxidase-IN-6 (Compound 6c) (0-20 mg/kg; i.g.; once daily for 2 weeks) shows anti-hyperuricemic effects, alleviates kidney damage, and inhibits XOD activity in a dose-dependent manner^[1].
Xanthine oxidase-IN-6 (0-20 mg/kg; i.g.; once daily for 2 weeks) effectively reduces renal fibrosis and inflammation^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Kunming mice (male, weight 20 ± 2 g). Hyperuricemic mouse model established by administering 0.5% CMC-Na (10 mL/kg), adenine (200 mg/kg) and potassium oxonate (500 mg/kg); oral gavage once daily for 2 or 4 weeks^[1].
Dosage:	5, 10 and 20 mg/kg
Administration:	Gavage, once daily for 2 weeks
Result:	Effectively decreased the levels of SUA, Cr, and BUN, effectively inhibited XOD activity and urate accumulation in a dose-dependent manner. Remarkedly improved the morphologic lesions with less fibrosis in the interstitium. Reduced the production of multiple cytokines (TNF-α, IL-8, and IL-1β). Reduced the expression of α-SMA, collagen I, TLR4, NF-κB, IκBα and TNF-α.

Molecular Weight

650.58

Formula

C₂₉H₃₄N₂O₁₅

SMILES

[H][C@]12CC=C([C@]1(C(OC=C2C(NC3=NC=CO3)=O)O[C@@H]4O[C@@H]([C@H]([C@@H]([C@H]4OC(C)=O)OC(C)=O)OC(C)=O)COC(C)=O)[H])COC(C)=O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Handling Instructions (2659 KB)

References

[1]. Jia-shu Chen, et al. Synthesis and biological evaluation of geniposide derivatives as inhibitors of hyperuricemia, inflammatory and fibrosis. Eur J Med Chem. 2022 Apr 20;237:114379. [Content Brief]